Menu

CDT Equity Inc. CDT

Full chart Compare
Set alert

Price alert · CDT

All alert types
0.84 USD -0.47 (-35.87%)

At closeNov 9, 2026, 7:58 PM EST

0.84 0.00 -0.54%

After hours · Nov 9, 7:58 PM ET

0.85 Day range 1.08
0.84 52-week range 332,500.00
YTD
-100.00%
1 year
-100.00%
Market cap
855.11K
EPS (ttm)
1,816,250.00
Shares out
119.86M
P/E ratio
0.00
YTD return
-100.00%
1-year return
-100.00%
Volume
3.34M
Avg volume
778.63K
Open
1.07
Previous close
1.31
Day's range
0.85 – 1.08
52-week range
0.84 – 332,500.00
Beta
2.12

5D -0.4799 (-36.36%)

0.80001.00001.20001.4000TueWedThuFriMon0.8401

Key statistics

Enterprise value
9.85M
PEG ratio
0.00
Price / sales
0.00
Price / book
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
0.00%
Free cash flow
0
Total cash
433.00K
Total debt
1.27M
Return on equity
0.00%
Short % of float
5.42%
50-day average
0.09784
200-day average
1.22

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
CDT Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CDT Net income — quarterly -4.64M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CDT EPS — quarterly -4,355.00
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

About CDT Equity Inc.

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on CDT — it syncs with the Stock Master app.

Insider holders

CDT insider holders
InsiderRelationLatest transactionDateShares held
BLIGH JAMESChief Financial OfficerStock Award(Grant)Jun 10, 202437,272
CHARLES FAITH L.DirectorStock Award(Grant)Nov 17, 2024341,594
FARLEY CHELE CHIAVACCIDirectorStock Award(Grant)Nov 17, 2024351,510
HEILBRON JACK KENDRICKFormerConversion of Exercise of derivative securitySep 21, 20230
LEWIS-HALL FREDA CDirectorStock Award(Grant)Nov 17, 20242,958,290
REGAN ANDREW J.Director and Beneficial Owner of more than 10% of a Class of SecuritySaleJul 16, 20240

Institution ownership

CDT institution ownership
Holder% heldSharesValueReported
Barclays Plc0.70%837,82745.66KSep 29, 2024
Blackrock Inc.0.63%755,61341.18KSep 29, 2024
Geode Capital Management, LLC0.36%427,67723.31KSep 29, 2024
Vanguard Group Inc0.30%361,71119.71KSep 29, 2024
Qube Research & Technologies Ltd0.27%318,35917.35KSep 29, 2024
Citadel Advisors Llc0.16%189,99010.35KSep 29, 2024

Fund ownership

CDT fund ownership
Holder% heldSharesValueReported
Fidelity Small Cap Index Fund0.19%233,35412.72KAug 30, 2024
Vanguard Extended Market Index Fund0.17%202,93411.06KSep 29, 2024
iShares Micro Cap ETF0.09%111,5756.08KOct 30, 2024
iShares Russell 2000 Value ETF0.09%105,9495.77KOct 30, 2024
iShares Russell 2000 Growth ETF0.09%103,2335.63KOct 30, 2024
Vanguard Russell 2000 Index Fund0.08%92,7565.05KAug 30, 2024